Scalper1 News
Specialty drugmaker and IBD 50 stock Jazz Pharmaceuticals reported Q2 earnings in line with estimates and affirmed its guidance late Wednesday, but its revenue came up a bit short of expectations. Jazz (JAZZ) said that its earnings rose 19% over the year-earlier quarter to $2.41 a share, while revenue increased 15% to $333.7 million. Analysts expected $335.9 million in revenue. The EPS number matched their estimate, according to Thomson Reuters. Scalper1 News
Scalper1 News